Vaccination programs are among the most successful and cost-effective public health strategies for preventing infections. Until recently, most of the existing immunization programs targeted infants and children younger than 5 years which have successfully resulted in reducing global infant and child mortality [@bib1]. As a result, adolescent immunization has been overshadowed, leaving a quarter of world\'s population vulnerable to a number of preventable diseases. Estimates suggest that around 35 million American adolescents fail to receive at least one recommended vaccine [@bib2]. In 2012, only half of the adolescent girls in the United States received a single dose of human papillomavirus (HPV) vaccine while merely 43% and 33% received two and three doses, respectively [@bib3]. Missed vaccination opportunities for adolescent vaccination against tetanus, diphtheria, pertussis (TDaP), tetravalent meningococcal conjugate vaccine, and HPV are also common in the United States since adolescents are less likely to utilize preventive care [@bib4].

Infectious and vaccine-preventable diseases disproportionately affect the low- and middle-income countries (LMICs) and disadvantaged populations in high-income countries (HICs). There were an estimated 266,000 deaths from cervical cancer worldwide in 2012, accounting for 7.5% of all female cancer deaths, of which nearly 85% occurred in developing countries [@bib5]. The worldwide prevalence of infection with HPV in women without cervical abnormalities is 11%--12% with higher rates in Sub-Saharan Africa (24%), Eastern Europe (21%), and Latin America (16%) [@bib6]. The proportion of invasive cervical cancer cases is higher in the LMICs with a relatively higher mortality/incidence ratio compared to the HICs [@bib7], [@bib8]. In U.S. settings, African-American girls were less likely to have either initiated or completed the three-dose HPV vaccination series [@bib9]. This warrants an additional focus on adolescents from LMICs and underprivileged populations in HICs as they also deserve a healthy transition into adulthood.

The recommended immunization during adolescence by the World Health Organization includes three doses of hepatitis B (for high-risk groups if not previously immunized), Td booster, one dose of rubella (adolescent girls and/or childbearing-aged women if not previously vaccinated), and two doses of HPV for females (9--14 years) and three doses for those aged 15 years and above [@bib10]. Low immunization rates in adolescents have a wide array of implications: outbreaks of vaccine-preventable diseases, negative effects on quality of life, and increased disease associated costs. Importantly, low immunization rates establish reservoirs of disease in adolescents that can affect others, including high-risk infants, elderly persons, and persons with underlying medical conditions.

Adolescent vaccination is a growing topic that has received significantly more attention since the advent of the HPV vaccine in 2006. In recent years, large number of programs have been launched to increase the uptake of different vaccines in adolescent populations; however, the recommended vaccination coverage among adolescents still remains low. These changes reflect an increased emphasis on the importance of adolescent immunization, but by themselves they will not sufficiently increase awareness or immunization rates [@bib1]. The American Academy of Pediatrics suggests implementing one or more of the strategies including reminder calls, prompts or standing orders, strong provider recommendation, including all recommended vaccination at every visit, provider feedback, educating patients and their parents, addressing costs, and setting up vaccination clinics to increase immunization coverage in adolescents [@bib11].

This article is part of a series of reviews conducted to evaluate the effectiveness of potential interventions for adolescent health and well-being. Detailed framework, methodology, and other potential interventions have been discussed in separate articles [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]. In this article, we systematically reviewed published literature to ascertain the effectiveness of interventions to improve immunization coverage among adolescents.

Methods {#sec1}
=======

We reviewed all literature published up to December 2014 to identify studies on interventions to improve vaccination coverage. We did not restrict our search to any time limits or geographical settings. For the purpose of this review, the adolescent population was defined as aged 11--19 years; however, since many studies targeted youth along with adolescents, exceptions were made to include studies targeting adolescents and youth. Based on the current recommended vaccines for adolescents [@bib19], search was conducted to identify studies focusing on improving coverage for HPV; measles, mumps, rubella (MMR); TDaP; meningococcal conjugate vaccine; and varicella vaccines among adolescents and youth. Studies were excluded if they targeted age groups other than adolescents and youth or did not report segregated data for the age group of interest. Studies were excluded if the intervention was aimed at comparing the efficacy/effectiveness of different vaccine preparations, assessing changes in antibody titers in individual subjects, or comparing various modes of delivering vaccines without control or baseline data.

Our priority was to select existing randomized controlled trials (RCTs), quasitrials, and before--after studies in which the intervention was directed toward the adolescent and youth and reported immunization coverage outcomes. Search strategy was developed using appropriate keywords, medical subject heading, and free text terms. The following principal sources of electronic reference libraries were searched to access the available data: The Cochrane Library, Medline, PubMed, Popline, LILACS, CINAHL, EMBASE, World Bank\'s JOLIS search engine, CAB Abstracts, British Library for Development Studies at IDS, the World Health Organization regional databases, Google, and Google Scholar. The titles and abstracts of all studies identified were screened independently by two reviewers for relevance and matched. Any disagreements on selection of studies between these two primary abstractors were resolved by the third reviewer. After retrieval of the full texts of all the studies that met the inclusion/exclusion criteria, data from each study were abstracted independently and in duplicate into a standardized form. Studies that met the inclusion criteria were selected and double data abstracted on a standardized abstraction sheet. Quality assessment of the included RCTs was done according to the Cochrane risk of bias assessment tool. We conducted a meta-analysis for individual studies using the software Review Manager, version 5.3 (Cochrane Collaboration, London, United Kingdom). Pooled statistics were reported as the relative risk (RR) for categorical variables and standard mean difference for continuous variables between the experimental and control groups with 95% confidence intervals (CIs). A grade of "high," "moderate," "low," and "very low" was used for grading the overall evidence indicating the strength of an effect on specific health outcome according to the Grading of Recommendations Assessment, Development and Evaluation criteria [@bib20].

Results {#sec2}
=======

[Figure 1](#fig1){ref-type="fig"} describes the search flow while characteristics of the included studies are detailed in [Table 1](#tbl1){ref-type="table"}. The search yielded 10,274 titles across all databases that were screened for the purpose of this review. Screening the relevant abstracts resulted in 51 full texts that were further screened after which 23 studies were included in this review [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], of which four were RCTs, three quasirandomized trials, and 16 before--after studies. Of the 23 included studies, seven [@bib26], [@bib27], [@bib28], [@bib29], [@bib31], [@bib32] focused on the HPV, 11 studies [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43] implemented interventions to improve coverage of multiple vaccines recommended for adolescents while measles [@bib21], MMR [@bib22], varicella [@bib23], rubella [@bib25], and TDaP [@bib24] vaccines were assessed in one study each. All the studies were conducted in HICs of the United States, Canada, Australia, Denmark, and England. Included studies mainly focused on evaluating the impact of licensing and mass provision of vaccines as a part of national-level vaccination program to increase provision and coverage of adolescent vaccination, availability of free vaccines, implementing vaccination requirement before entry into school, reminder letters, telephone calls, and training of clinic staff on adolescent vaccines and strategies to improve immunization rates. Target populations in all studies were adolescents aged 11--19 years except three studies in the HPV vaccine category that targeted adolescents and youth till the age of 24 years.

Moderate-quality evidence from 13 studies suggested an overall increase in vaccination coverage by 78% (RR: 1.78; 95% CI: 1.41--2.23; [Figure 2](#fig2){ref-type="fig"}) [@bib30], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43]. Subgroup analysis suggests that vaccination requirement in school, reminders, and national permissive recommendation had a significant impact on improving coverage while clinic staff training showed a nonsignificant impact. Strategies to improve coverage for HPV vaccines including countrywide provision and clinic-based delivery resulted in a significant decrease in the prevalence of HPV by 44% (RR: .56; 95% CI: .38--.82; [Figure 3](#fig3){ref-type="fig"}) [@bib28], [@bib29] and genital warts by 33% (RR: .66; 95% CI: .52--.84; [Figure 4](#fig4){ref-type="fig"}) [@bib26], [@bib27], [@bib31]; however, the quality of evidence was low. Since only one study each was included for measles, mumps, pertussis, and varicella vaccines, it was not possible to pool results. Analysis from single studies with low or very low quality suggested significant decrease in varicella deaths (RR: .74; 95% CI: .56--.98), measles incidence (RR: .12; 95% CI: .03--.38), rubella susceptibility (RR: .27; 95% CI: .15--.46), and incidence of pertussis (RR: .24; 95% CI: .16--.36) while the impact was nonsignificant for incidence of mumps (RR: .96; 95% CI: .42--2.18).

The outcome quality was rated to be "moderate" for vaccine coverage; "low" for the prevalence of HPV, genital warts, and mump incidence; and "very low" for varicella deaths, measles incidence, rubella susceptibility, and incidence of pertussis. The outcome quality was downgraded due to nonrobust designs, heterogeneity, and limited generalizability to HICs only. A summary of quality of evidence is provided in [Table 2](#tbl2){ref-type="table"}.

Discussion {#sec3}
==========

Our review findings suggest that strategies to increase HPV, TDaP, MMR, and varicella vaccination uptake among adolescents can significantly improve the coverage for these vaccines. Implementing vaccination requirement in school, sending reminders, and national permissive recommendation for adolescent vaccination has the potential to improve immunization uptake. These interventions have also led to significant decline in the prevalence of HPV and genital warts; incidence of measles and pertussis; rubella susceptibility; and varicella deaths. However, these findings should be interpreted with caution since these are from single studies with low or very low quality. Furthermore, these studies capture the incremental benefits of vaccination of those who may have missed earlier doses or failed to seroconvert to earlier doses since these vaccines are usually given at younger ages.

All the included studies were conducted in HICs depicting dearth of evidence evaluating the effectiveness of strategies to improve immunization uptake among adolescent from LMICs. This could also be attributable to the scope of review since our review was restricted to strict inclusion and exclusion criteria, and we did not include gray literature reporting various country case studies. Furthermore, recent state mandatory vaccination and exception policies could also have affected the vaccination coverage rates; however, these programs and policy interventions do not lend themselves to intervention studies. One of the limitations of the review was that the search terms were in English, and hence foreign language articles may not have been identified. There is lack of rigorously designed studies since most of the existing studies have utilized the pre- and postimplementation data after the approval of vaccine legislation or national launch of vaccination program without having a control site. Only a single study each for MMR, TDaP, varicella, and meningococcal vaccines were found, showing a lack of focus evaluating the impact of uptake for vaccines other than HPV. This highlights the need for further studies to assess the uptake and delivery platforms to deliver these vaccines in adolescent population. Included studies targeted various overlapping adolescent and youth age groups that might have led to variations in the outcome effect.

Despite the high burden of infectious diseases and low immunization coverage in LMICs, strategies to improve vaccine coverage for adolescent age group are minimal. Although there are existing data outlining what exists in LMICs for delivering adolescent immunization, primarily through school-based approaches; however, there are little data that have systematically been evaluated for the impact of strategies to increase coverage [@bib44]. Various countries\' case studies have documented experiences from LMICs with existing school-based immunization programs, for example, in Indonesia, Malaysia, Sri Lanka, and Tunisia; however, they lack rigorous evaluations [@bib45]. For HPV, various national-level programs are in place especially in LMICs; Bhutan is the first LMIC to roll out a national HPV vaccination program, followed by Rwanda and Uganda. These programs suggest that vaccine uptake can be improved by providing evidence-based education and outreach; however, experiences in these countries underscore complex challenges and planning to ensure sustainability [@bib46]. The number of LMICs that have introduced HPV vaccination is relatively low; however, the coverage levels in these countries are relatively higher than in some HIC. Enabling factors for improved coverage in LMICs include political will, nationwide sensitization campaign, school-based vaccination, and community involvement [@bib44], [@bib45], [@bib46], [@bib47].

Despite the availability of the HPV vaccine in HICs like the United States, the uptake remains low. Vaccine utilization is a multifactorial phenomenon which depends on several factors including vaccine acceptability, perceived disease susceptibility, perceived benefit of vaccination, and intention to receive the particular vaccine. A recent systematic review on barriers to HPV vaccination among adolescents in the United States suggests financial concerns and parental attitudes as barriers to HPV vaccination [@bib48], [@bib49]. Good understanding and knowledge of the factors and importance of vaccine in target population are important for tailoring vaccine improvement strategies and subsequent success of the program in achieving targeted vaccine coverage [@bib50]. It is imperative to develop and test context-specific strategies to improve adolescent vaccine uptake and dose completion rates. Educational interventions could increase knowledge and clear misconceptions related to seriousness of vaccine-preventable infection and cervical cancer, susceptibility of adolescents to infection, and risk of infection. Such strategies would also address barriers to adolescent vaccine uptake and dose completion, such as parental concerns about vaccine safety, and effectiveness [@bib51]. Very few of the included studies in our review utilized mHealth/eHealth technology for improving immunization coverage which could be one of the potentially effective strategies to target adolescent age group especially in LMIC settings owing to the higher use in this age group and recent explosion in Internet access in developing countries due to the emergence of mobile Internet [@bib52]. One of the concerns with the introduction of HPV vaccine in low-resourced high-burden countries is lack of cost-effective data; however, some recent analysis suggests that HPV vaccination is likely to be cost-effective, especially in LMICs [@bib53], [@bib54].

Improving vaccination coverage to decrease the burden of these preventable diseases would require an integrated approach ranging from mass availability of vaccines at the national level to targeting adolescents in school and during health care visits to optimize the effectiveness of immunization programs. Besides these programs, there is a need for an increased emphasis on the importance of adolescent immunization by identifying and overcoming barriers to adolescent vaccination. Further research is needed to explore why missed vaccination opportunities occur and to develop evidence-based strategies to reduce missed opportunities and improve adolescent vaccination coverage.
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###### 

Characteristics of included studies

  Study                          Study design    Country         Setting                     Intervention                                                                                                                                                                                                                                                               Target population                              Control                                                                          Outcomes assessed
  ------------------------------ --------------- --------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------
  Measles                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   Zhuo et al. [@bib21]          Before--after   China           Community                   Supplementary immunization activities                                                                                                                                                                                                                                      All ages                                       No supplementary immunization activity                                           Incidence of measles
  MMR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Ogbuanu et al. [@bib22]       Before--after   United States   School                      Selective school-based immunization                                                                                                                                                                                                                                        9--14 years                                    No intervention                                                                  Incidence of mumps
  Varicella                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
   Nguyen et al. [@bib23]        Before--after   United States   Nationwide vaccination      Universal childhood varicella vaccination program                                                                                                                                                                                                                          All ages (outcome assessed for 10--19 years)   Before implementation of childhood varicella immunization                        Number of deaths caused by varicella infection
  TDaP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
   Quinn and McIntyre [@bib24]   Before--after   Australia       School                      School-based delivery of TDaP                                                                                                                                                                                                                                              12--19 years                                   Nonavailability of school-based immunization                                     Incidence of pertussis
  Rubella                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   Nelson et al. [@bib25]        Before--after   United States   School                      Vaccination requirement in school                                                                                                                                                                                                                                          Girls older than 10 years                      Before the vaccination requirement                                               Rubella susceptibility
  HPV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Baandrup et al. [@bib26]      Before--after   Denmark         Countrywide provision       Licensing and mass provision of HPV as part of National HPV Program                                                                                                                                                                                                        12--19 years                                   Absence of nationwide HPV availability                                           Incidence of genital warts
   Bauer et al. [@bib27]         Before--after   United States   Countrywide provision       Introduction population-level administration of HPV vaccine                                                                                                                                                                                                                \<21 years                                     Nonavailability of population-level vaccination                                  Incidence of genital warts
   Markowitz et al. [@bib28]     Before--after   United States   Countrywide provision       Introduction of HPV vaccine into routine immunization schedule                                                                                                                                                                                                             14- to 24-year-old females                     HPV vaccine not included in routine immunization schedule                        Prevalence of HPV
   Mesher et al. [@bib29]        Before--after   England         Countrywide provision       Introduction of National HPV Immunization Program                                                                                                                                                                                                                          16- to 24-year-old females                     Nonavailability of population-level vaccination                                  Prevalence of HPV
   Musto et al. [@bib30]         Quasitrial      Canada          School and community        Within schools vaccination during Grades 1, 5, and 9                                                                                                                                                                                                                       9- to 11- and 13- to 15-year-old females       Community-based vaccine availability at local community clinics by appointment   Vaccine uptake
   Read et al. [@bib31]          Before--after   Australia       Clinic                      Introduction of National HPV Vaccination Program                                                                                                                                                                                                                           12- to 18-year-old females                     HPV vaccine not included in national immunization schedule                       Incidence of genital warts
   Reiter et al. [@bib32]        Before--after   United States   Nationwide recommendation   National permissive recommendation for HPV vaccine                                                                                                                                                                                                                         11- to 17-year-old males                       No recommendation                                                                Vaccine initiation
  Multivaccine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
   Averhoff et al. [@bib33]      Before--after   United States   School                      Vaccination requirement in school                                                                                                                                                                                                                                          Fifth- through eighth-grade students           Students not subject to the requirement                                          Vaccine coverage
   Bugenske et al. [@bib34]      Quasitrial      United States   School                      Vaccination requirement in school                                                                                                                                                                                                                                          13--17 years                                   Students not subject to the requirement                                          Vaccine coverage
   Carlson and Lewis [@bib35]    Before--after   Canada          School                      Vaccination requirement in school                                                                                                                                                                                                                                          Grades 7--13                                   Students not subject to the requirement                                          Vaccine coverage
   Fogarty et al. [@bib36]       Before--after   United States   School                      Vaccination requirement in school                                                                                                                                                                                                                                          Seventh-grade students                         No control                                                                       Vaccine coverage
   Harper and Murray [@bib37]    Quasitrial      United States   Clinic                      Clinic staff recommended vaccine on every visit                                                                                                                                                                                                                            11--18 years                                   No recommendation                                                                Vaccine coverage
   Kempe et al. [@bib38]         RCT             United States   School                      Recall reminders for vaccination                                                                                                                                                                                                                                           Sixth-grade male students                      No recommendation                                                                Vaccine coverage
   Kharbanda et al. [@bib39]     Before--after   United States   Hospital                    Vaccination requirement in school                                                                                                                                                                                                                                          11--14 years                                   Students not subject to the requirement                                          Vaccine coverage
   Moss et al. [@bib40]          Before--after   United States   Clinic                      Clinic staff were invited to attend 1-hour one-on-one webinar on adolescent vaccines and strategies to improve immunization rates such as reviewing and flagging charts, decreasing missed opportunities, recalls, and establishing center guidelines for immunizations.   12--17 years                                   No staff training                                                                Vaccine coverage
   Stockwell et al. [@bib41]     RCT             United States   Community                   Text message reminders for vaccination                                                                                                                                                                                                                                     12--18 years                                   No reminder                                                                      Vaccine coverage
   Suh et al. [@bib42]           RCT             United States   Clinic                      Reminders letters and calls for vaccination                                                                                                                                                                                                                                11--18 years                                   No reminder                                                                      Vaccine coverage
   Szilagyi et al. [@bib43]      RCT             United States   Clinic                      Mail letters and telephone reminders for vaccination                                                                                                                                                                                                                       11--17 years                                   No reminder                                                                      Vaccine coverage

HPV = human papillomavirus; MMR = measles, mumps, rubella; RCT = randomized controlled trial; TDaP = tetanus, diphtheria, pertussis.

###### 

Summary of findings for the effect of interventions for improving immunization coverage among adolescents

  Quality assessment                                                      Summary of findings                                                                                                                                                                                                                                                                                                                                   
  ----------------------------------------------------------------------- --------------------------------------- ------------------------------- ----------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------- ------- -------------------
  Vaccine coverage: moderate outcome-specific quality of evidence                                                                                                                                                                                                                                                                                                                                                               
   13 studies (14 data sets)                                              RCT, quasi, and observational studies   Study designs not robust        Twelve studies suggest benefit      All studies targeted adolescents aged 11--19 years in developed countries                                   Interventions included vaccination requirement in school, reminders, and national permissive recommendation   5,092   4,303   1.78 (1.41--2.23)
  HPV prevalence: low outcome-specific quality of evidence                                                                                                                                                                                                                                                                                                                                                                      
   Two studies                                                            Observational studies                   Study designs not robust        Both studies suggest benefit        Studies targeted adolescents aged 14--24 years in developed countries                                       Intervention included introducing HPV vaccine into routine immunization                                       499     554     .56 (.38--.82)
  Incidence of genital warts: low outcome-specific quality of evidence                                                                                                                                                                                                                                                                                                                                                          
   Three studies                                                          Observational studies                   Study designs not robust        All three studies suggest benefit   All studies from developed countries targeting adolescents from age 12 to 21 years                          All studies focused on increased provision of HPV vaccine through national HPV programs                       3,875   5,409   .66 (.52--.84)
  Varicella deaths: very low outcome-specific quality of evidence                                                                                                                                                                                                                                                                                                                                                               
   One                                                                    Observational study                     Study design not robust         Only one study                      Intervention targeted all age groups in the United States, outcomes reported for 10- to 19-year age group   Universal childhood varicella vaccination program                                                             77      104     .74 (.56--.98)
  Mumps incidence: low outcome-specific quality of evidence                                                                                                                                                                                                                                                                                                                                                                     
   One                                                                    Quasitrial                              No randomization (quasitrial)   Only one study                      Adolescents 9--14 years in the United States                                                                School-based immunization                                                                                     28      7       .96 (.42--2.21)
  Pertussis incidence: very low outcome-specific quality of evidence                                                                                                                                                                                                                                                                                                                                                            
   One                                                                    Observational study                     Study design not robust         Only one study                      Interventions targeted adolescents 12--19 years in Australia                                                School-based delivery of TDaP vaccine                                                                         31      128     .24 (.16--.36)
  Rubella susceptibility: very low outcome specific quality of evidence                                                                                                                                                                                                                                                                                                                                                         
   One                                                                    Observational study                     Study design not robust         Only one study                      Interventions targeted adolescent girls \>10 years in the United States                                     Vaccination requirement in school                                                                             15      49      .27 (.15--.46)
  Measles incidence: very low outcome-specific quality of evidence                                                                                                                                                                                                                                                                                                                                                              
   One                                                                    Observational study                     Study design not robust         Only one study                      Interventions targeted all ages in China                                                                    Supplementary immunization activities                                                                         3       26      .12 (.03--.38)

CI = confidence interval; HPV = human papillomavirus; RCT = randomized controlled trial; RR = relative risk; TDaP = Tetanus, diphtheria, pertussis.
